Bio-Techne shareholders will receive $73 per share in cash, representing a 36% premium to the company’s one-month volume-weighted average trading price.
The deal has already been approved by Bio-Techne’s board and the relevant corporate bodies of Merck KGaA and is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals.
Expanding Life Science Capabilities Across Key Growth Areas
Merck KGaA said the acquisition aligns with its medium- and long-term strategy focused on high-growth areas, integrated workflows, and innovation through mergers and acquisitions.
The combination would unite two life sciences companies with complementary portfolios spanning discovery, translational research, development, testing, and commercial manufacturing.
